Polyol pathway and diabetic nephropathy revisited: Early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase

Journal of Diabetes Investigation

Volumn 2, Issue 2, 2011, Pages 111-122

  Hashimoto, Yasuhiro ^a   Yamagishi, Shin Ichiro ^a   Mizukami, Hiroki ^a   Yabe Nishimura, Chihiro ^b   Lim, Sun Woo ^c   Kwon, H Moo ^c   Yagihashi, Soroku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Aldose reductase; Diabetic nephropathy; Tubuloglomerular feedback system

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; BINDING PROTEIN; POLYOL; STREPTOZOCIN; TONICITY RESPONSIVE ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL DEGENERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; GENE OVEREXPRESSION; GLOMERULOPATHY; KIDNEY HYPERTROPHY; KIDNEY MASS; KIDNEY STRUCTURE; KIDNEY TUBULE CELL; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; WILD TYPE;

EID: 79961034723     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00071.x     Document Type: Article

References (43)

1. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
2. Kinoshita JH, Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 1988; 4: 323-337.
3. Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia 1992; 35: 499-504.
4. Pugliese G, Pricci F, Pugliese F, et al. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes 1994; 43: 478-490.
5. Jiang T, Che Q, Lin Y, et al. Aldose reductase regulates tgf-beta1-induced production of fibronectin and type iv collagen in cultured rat mesangial cells. Nephrology (Carlton) 2006; 11: 105-112.
6. Goldfarb S, Ziyadeh FN, Kern EF, et al. Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991; 40: 465-471.
7. Beyer-Mears A, Mistry K, Diecke FP, et al. Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. Pharmacology 1996; 52: 292-302.
8. Mauer SM, Steffes MW, Azar S, et al. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats. Diabetes 1989; 38: 839-846.
9. Pedersen MM, Christiansen JS, Mogensen CE. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes 1991; 40: 527-531.
10. Shah VO, Scavini M, Nikolic J, et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab 1998; 83: 2886-2891.
11. Hamada Y, Kitoh R, Raskin P. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 1991; 40: 1233-1240.
12. Maeda S, Haneda M, Yasuda H, et al. Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (alr2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes. Diabetes 1999; 48: 420-422.
13. Yagihashi S, Wada R, Yamagishi S-I, et al. Polyol-related pathway and its pathological abnormality: evaluation of the transgenic mice which express human aldose reductase. In:BabaS,KanekoT(eds).Diabetes 1994. Elsevier Sci Publ BV, Amsterdam, Netherland: 1995; 326-330.
14. Yamaoka T, Nishimura C, Yamashita K, et al. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 1995; 38: 255-261.
15. Yagihashi S, Yamagishi S, Wada R, et al. Galactosemic neuropathy in transgenic mice for human aldose reductase. Diabetes 1996; 45: 56-59.
16. Uehara K, Yamagishi S, Otsuki S, et al. Effects of polyol pathway hyperactivity on protein kinase c activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 2004; 53: 3239-3247.
17. Hwang YC, Kaneko M, Bakr S, et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 2004; 18: 1192-1199.
18. Iwata K, Matsuno K, Nishinaka T, et al. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci 2006; 102: 37-46.
19. Nishimura C, Yamaoka T, Mizutani M, et al. Purification and characterization of the recombinant human aldose reductase Polyol pathway and diabetic nephropathy expressed in baculovirus system. Biochim Biophys Acta 1991; 1078: 171-178.
20. Hogan B, Constantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1986.
21. Sassy-Prigent C, Heudes D, Jouquey S, et al. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ace inhibition. Lab Invest 1995; 73: 64-71.
22. Jensen EB, Gundersen HJ, Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J Microsc1979; 115: 19-33.
23. Terubayashi H, Sato S, Nishimura C, et al. Localization of aldose and aldehyde reductase in the kidney. Kidney Int 1989; 36: 843-851.
24. Cha JH, Woo SK, Han KH, et al. Hydration status affects nuclear distribution of transcription factor tonicity responsive enhancer binding protein in rat kidney. J Am Soc Nephrol 2001; 12: 2221-2230.
25. Nagai R, Unno Y, Hayashi MC, et al. Peroxynitrite induces formation of n(ε)-(carboxymethyl) lysine by the cleavage of amadori product and generation of glucosone and glyoxal from glucose: Novel pathways for protein modification by peroxynitrite. Diabetes 2002; 51: 2833-2839.
26. Zhang Z, Ferraris JD, Brooks HL, et al. Expression of osmo-tic stress-related genes in tissues of normal and hypos-motic rats. Am J Physiol Renal Physiol 2003; 285: F688-F693.
27. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 2005; 12: 177-186.
28. Ferraris JD, Williams CK, Jung KY, et al. ORE, a eukaryotic minimal essential osmotic response element. The aldose reductase gene in hyperosmotic stress. J Biol Chem 1996; 271: 18318-18321.
29. Neuhofer W, Woo SK, Na KY, et al. Regulation of tonEBP transcriptional activator in mdck cells following changes in ambient tonicity. Am J Physiol Cell Physiol 2002; 283: C1604-C1611.
30. Soulis-Liparota T, Cooper ME, Dunlop M, et al. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995; 38: 387-394.
31. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
32. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813.
33. Tilton RG, Chang K, Pugliese G, et al. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989; 38: 1258-1270.
34. Lynch JJ, Ferro TJ, Blumenstock FA, et al. Increased endothelial albumin permeability mediated by protein kinase c activation. J Clin Invest 1990; 85: 1991-1998.
35. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
36. Sugimoto H, Shikata K, Matsuda M, et al. Increased expres-sion of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998; 41: 1426-1434.
37. Yagihashi N, Nishida N, Seo HG, et al. Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats. Diabetologia 1996; 39: 793-799.
38. Robinson WG Jr, Laver NM, Jacot JL, et al. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor way-121,509. Invest Ophthalmol Vis Sci 1996; 37: 1149-1156.
39. Chakrabarti S, Sima AA. Effect of aldose reductase inhibition and insulin treatment on retinal capillary basement membrane thickening in bb rats. Diabetes 1989; 38: 1181-1186.
40. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
41. Sato T, Iwaki M, Shimogaito N, et al. TAGE (toxic ages) theory in diabetic complications. Curr Mol Med 2006; 6: 351-358.
42. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. JAm Soc Nephrol 1999; 10: 822-832.
43. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.